New study tracks Real-World success of IBD drug guselkumab
NCT ID NCT07102368
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 21 times
Summary
This study follows 400 people with Crohn's disease or ulcerative colitis who are starting guselkumab, a biologic drug. Researchers will measure how many achieve remission and how the drug affects fatigue, quality of life, and daily activities. The goal is to see how well the treatment works outside of controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Praxis Fur Gastroenteroligie
RECRUITINGBerlin, 10825, Germany
Conditions
Explore the condition pages connected to this study.